Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M96,847Revenue $M9,703Net Margin (%)30.3Z-Score18.7
Enterprise Value $M91,335EPS $12.4Operating Margin %40.8F-Score9
P/E(ttm))33.3Cash Flow Per Share $7.4Pre-tax Margin (%)40.7Higher ROA y-yY
Price/Book9.010-y EBITDA Growth Rate %26.5Quick Ratio1.7Cash flow > EarningsY
Price/Sales10.15-y EBITDA Growth Rate %25.5Current Ratio2.1Lower Leverage y-yY
Price/Cash Flow20.5y-y EBITDA Growth Rate %54.7ROA % (ttm)22.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)30.2Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M235ROI % (ttm)19.7Gross Margin Increase y-yY

Gurus Latest Trades with BIIB

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BIIBRay Dalio 2014-12-31 Add0.04%$299.1 - $360.67
($323.29)
$ 412.7928%Add 820.17%15,146
BIIBKen Heebner 2014-12-31 Sold Out -0.75%$299.1 - $360.67
($323.29)
$ 412.7928%Sold Out0
BIIBVanguard Health Care Fund 2014-12-31 Sold Out -0.2%$299.1 - $360.67
($323.29)
$ 412.7928%Sold Out0
BIIBJoel Greenblatt 2014-12-31 Reduce-0.08%$299.1 - $360.67
($323.24)
$ 412.7928%Reduce -84.03%5,012
BIIBKen Heebner 2014-09-30 Buy 0.75%$299.29 - $346.3
($329.79)
$ 412.7925%New holding, 80000 sh.80,000
BIIBJoel Greenblatt 2014-09-30 Buy 0.1%$299.29 - $346.3
($329.79)
$ 412.7925%New holding, 31391 sh.31,391
BIIBRay Dalio 2014-09-30 Buy $299.29 - $346.3
($329.79)
$ 412.7925%New holding, 1646 sh.1,646
BIIBVanguard Health Care Fund 2014-09-30 Reduce-0.27%$299.29 - $346.3
($329.79)
$ 412.7925%Reduce -58.26%233,600
BIIBKen Fisher 2014-06-30 Add0.05%$274 - $320.13
($300.74)
$ 412.7937%Add 386.61%88,885
BIIBRon Baron 2014-06-30 Add$274 - $320.13
($300.74)
$ 412.7937%Add 41.76%8,632
BIIBKen Heebner 2014-06-30 Sold Out -0.95%$274 - $320.13
($300.74)
$ 412.7937%Sold Out0
BIIBAndreas Halvorsen 2014-06-30 Sold Out -0.5%$274 - $320.13
($300.74)
$ 412.7937%Sold Out0
BIIBGeorge Soros 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 412.7937%Sold Out0
BIIBJoel Greenblatt 2014-06-30 Sold Out -0.02%$274 - $320.13
($300.74)
$ 412.7937%Sold Out0
BIIBJohn Burbank 2014-06-30 Sold Out -0.01%$274 - $320.13
($300.74)
$ 412.7937%Sold Out0
BIIBKen Heebner 2014-03-31 Buy 0.95%$273.518 - $351.94
($316.4)
$ 412.7930%New holding, 116000 sh.116,000
BIIBAndreas Halvorsen 2014-03-31 Buy 0.5%$273.518 - $351.94
($316.4)
$ 412.7930%New holding, 388900 sh.388,900
BIIBGeorge Soros 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 412.7930%New holding, 7500 sh.7,500
BIIBJoel Greenblatt 2014-03-31 Buy 0.02%$273.518 - $351.94
($316.4)
$ 412.7930%New holding, 3931 sh.3,931
BIIBKen Fisher 2014-03-31 Add0.01%$273.518 - $351.94
($315.54)
$ 412.7931%Add 796.27%18,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BIIB is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BIIB Ray Dalio 2014-12-3115,1460.010.04+820.17%
BIIB Mario Gabelli 2014-12-314,93500.01+6.47%
BIIB Ron Baron 2014-12-319,14400.01+6.17%
BIIB Ken Fisher 2014-12-3179,2540.030.06+1.02%
BIIB Frank Sands 2014-12-314,974,3312.114+0.45%
BIIB PRIMECAP Management 2014-12-3117,170,6937.275.9-0.27%
BIIB Joel Greenblatt 2014-12-315,01200.01-84.03%
BIIB Vanguard Health Care Fund 2014-12-31000Sold Out
BIIB Ken Heebner 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BIIB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sandrock AlfredGrp SVP, Chief Medical Officer 2015-03-02Sell3,174$409.490.81view
SCANGOS GEORGE ACEO 2015-03-02Sell825$410.670.52view
SCANGOS GEORGE ACEO 2015-02-19Sell537$401.042.93view
Sandrock AlfredGrp SVP, Chief Medical Officer 2015-02-17Sell418$389.116.09view
DiPietro KennethEVP Human Resources 2015-02-17Sell1,188$389.116.09view
SCANGOS GEORGE ACEO 2015-02-17Sell825$389.116.09view
Holtzman Steven HEVP Corporate Development 2015-02-17Sell2,128$389.116.09view
Sandrock AlfredGrp SVP, Chief Medical Officer 2015-02-10Sell1,143$398.113.69view
Sandrock AlfredGrp SVP, Chief Medical Officer 2015-02-09Sell856$398.053.7view
DiPietro KennethEVP Human Resources 2015-02-02Sell1,656$389.036.11view

Press Releases about BIIB :

    Quarterly/Annual Reports about BIIB:

    News about BIIB:

    Articles On GuruFocus.com
    February Pick Of Biotech Stocks Feb 17 2015 
    Stanley Druckenmiller's Recent Trades Feb 13 2015 
    8 Strong Recommendations for 2015 Feb 13 2015 
    Google Joins Biogen In The Fight Against Multiple Sclerosis Jan 29 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
    Biogen’s Alzheimer’s Drug Moves to Phase III Dec 03 2014 
    Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
    Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
    Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 

    More From Our Partners
    Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog Mar 3 2015 - ZACKS

    More From Other Websites
    What Drugs Could Boost Biogen Idec’s Sales? Mar 03 2015
    Top Funds Buying Rackspace, Allergan, Biogen Idec, Apple Mar 03 2015
    Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog Mar 03 2015
    Big Cap 20 Reflecting Market Leadership Mar 02 2015
    Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Group’s Top... Mar 02 2015
    Biogen/Sobi Report Postive Phase III Data on Alprolix - Analyst Blog Mar 02 2015
    Isis Pharmaceuticals Up on Q4 Earnings and Revenues Beat - Analyst Blog Mar 02 2015
    Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix®... Feb 27 2015
    Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX®... Feb 27 2015
    Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX®... Feb 27 2015
    Medivation Tops Q4 Views On Strong Xtandi Results Feb 26 2015
    Neurotrope Moving Focus Upstream in Developing New Alzheimer’s Disease Drug and Drugs for Orphan... Feb 26 2015
    13F Filings Takeaway: Own A Dirty Dozen Feb 25 2015
    Nasdaq nears its Internet bubble-era record Feb 24 2015
    These five stocks are in the Nasdaq driver's seat Feb 24 2015
    United Therapeutics Blood Pressure Drug Lifts Q4 Feb 24 2015
    What's driving the Nasdaq? These 5 stocks Feb 24 2015
    Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires’ 5 Hottest Biotech Picks Feb 23 2015
    Cramer: We're in a bubble. So, what? Apple's cheap Feb 23 2015
    Monday's Market Recap Feb 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK